News

The acquisition will expand the company’s speciality pharmaceutical platform into severe infectious diseases. Completion is expected in the first quarter of fiscal 2026, subject to customary conditions. The

FOP is an ultra-rare condition, impacting fewer than 1,000 people worldwide. The collaboration involves containment, specialised handling, and sustained supply of this highly potent molecule. The agreement includes

The acquisition includes five sites specialising in various in vitro drug discovery services such as New Approach Methodologies (NAMs) and a small molecule AI platform. These assets are

Vivtex will license to Novo Nordisk select oral drug-delivery technologies and is set to receive research funding, upfront payments, and milestone payments up to $2.1bn, along with tiered

The funding coincides with the in-licensing of SLTE-1009, an anti-PACAP monoclonal antibody acquired from DartsBio Pharmaceuticals (Guangdong). The company is headed by CEO and board director Gregory Oakes,

The partnership brings together a high-titre glutamine synthetase (GS) knockout (−/−) Chinese hamster ovary (CHO) cell line solution, free from additional intellectual property costs, aiming to streamline the

This marks a key development in the potential approval of adrabetadex, which could become a disease-modifying treatment for this rare paediatric neurodegenerative disorder. The FDA set 17 August

These facilities will integrate advanced manufacturing technologies and AI for supporting production of the company’s obesity and next-generation neuroscience medications. Construction is scheduled to commence in spring 2026,

The approval was granted by the US Food and Drug Administration (FDA) and follows positive AMPLIFY Phase III trial results. This trial enrolled patients from 2019 to 2021.